Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Renal OCT2 and MATE1 Inhibition by 5-HT3 Antiemetics: Implic
2026-05-21
This study demonstrates that multiple 5-HT3 antagonist antiemetic drugs potently inhibit the renal transporters OCT2 and MATE1 in vitro, with significant differences in inhibitory potency among agents. These findings have direct implications for drug-drug interactions and the renal elimination of cationic therapeutics in clinical and preclinical research.
IWR-1-endo: Precision Wnt Pathway Inhibition for Translation
2026-05-21
Explore how IWR-1-endo, a nanomolar-potency Wnt signaling inhibitor from APExBIO, is redefining mechanistic studies in cancer and regenerative biology. This article bridges mechanistic insight, experimental best practices, and strategic foresight for translational researchers seeking to leverage Wnt/β-catenin modulation in next-generation disease models and therapeutic discovery.
Viral Targeting of RIPK3: Mechanisms Regulating Necroptosis
2026-05-20
Liu et al. (2021) identified a class of viral proteins that induce the degradation of RIPK3 via the SCF ubiquitin ligase complex, suppressing necroptosis and modulating virus-induced inflammation. Their findings reveal a distinct viral immune evasion strategy with implications for understanding host-pathogen interactions and regulated cell death.
LY2603618: Chk1 Inhibition Redefining Translational Oncology
2026-05-20
This article explores the mechanistic rationale and translational strategies for deploying LY2603618, a selective Chk1 inhibitor, in advanced cancer research. Integrating recent advances in DNA damage response modulation and personalized platforms such as iPSC-based prescreening, it provides actionable guidance for researchers seeking to leverage checkpoint kinase targeting for improved chemotherapy outcomes and precision oncology.
Cy5 NHS ester(Et): Technical Guide for Protein Labeling
2026-05-19
Cy5 NHS ester(Et) enables stable, water-soluble fluorescent labeling of primary amines in proteins and other biomolecules, supporting workflows in immunofluorescence, flow cytometry, and fluorescence microscopy. It is not suitable for ethanol-based protocols or for applications that require long-term storage of dye solutions.
Indomethacin in Inflammation Research: Protocols & Pitfalls
2026-05-19
Indomethacin stands as a powerful tool for dissecting inflammation, lipid metabolism, and membrane signaling in modern biomedical research. This article delivers actionable workflows, troubleshooting strategies, and expert insights to help researchers maximize reproducibility and data quality when using APExBIO’s Indomethacin.
Glabridin-Gold(I) Complex: Dual TrxR/MAPK Targeting Enhances
2026-05-18
This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase and MAPK pathways, remodeling the immunosuppressive tumor microenvironment in liver cancer. The dual-action complex promotes dendritic cell maturation, reduces immunosuppressive cell populations, and suppresses PD-L1 expression, highlighting a new approach for enhancing antitumor immunity in combination immunotherapy.
PD 173074 (SKU A8253): Precision FGFR1/VEGFR2 Inhibition for
2026-05-18
This article guides biomedical researchers through real-world experimental challenges involving FGFR and VEGFR2 signaling, highlighting how PD 173074 (SKU A8253) delivers nanomolar-selective, reproducible inhibition. Scenario-driven Q&As address protocol optimization, data clarity, and vendor reliability—empowering labs to leverage PD 173074’s validated performance for robust cancer research and pathway analysis.
Adefovir Dipivoxil: Mechanistic Efficacy in Chronic HBV Ther
2026-05-17
This article examines the pivotal findings of Hadziyannis & Papatheodoridis on adefovir dipivoxil’s role in chronic hepatitis B virus (HBV) treatment. The study establishes adefovir’s mechanistic selectivity, clinical robustness, and low resistance profile, shaping its use in both first-line and drug-resistant HBV scenarios.
HRP Goat Anti-Rabbit IgG (H+L) Antibody: Technical Guide
2026-05-16
The HRP Goat Anti-Rabbit IgG (H+L) Antibody addresses precise detection and signal amplification needs when working with rabbit primary antibodies in immunoassays. It is strictly intended for research applications and should not be used for diagnostic or medical purposes. Researchers benefit from its affinity purification and HRP conjugation, but must follow storage and handling protocols closely to maintain performance.
0.4% Trypan Blue Solution: Workflow Parameters and QC Guide
2026-05-15
0.4% Trypan Blue Solution provides a reliable method for distinguishing viable from non-viable cells in research workflows, supporting accurate cell viability measurement and cell counting. It is not suitable for diagnostic or therapeutic applications and should only be used in controlled scientific laboratory settings.
Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma
2026-05-15
This study demonstrates a tumor microenvironment-responsive nanoparticle system for systemic delivery of PTEN mRNA, effectively reversing trastuzumab resistance in HER2-positive breast cancer models. The findings provide mechanistic insights into overcoming PI3K/Akt-mediated therapy resistance, with direct applications for mRNA-based restoration of tumor suppressor function.
Olaparib (AZD2281) in BRCA-Targeted Cancer Research Workflow
2026-05-14
Olaparib (AZD2281) empowers precision DNA damage response assays and tumor radiosensitization studies, especially in models with homologous recombination defects. This article details actionable protocols, advanced applications, and troubleshooting strategies for maximizing Olaparib's impact in BRCA-associated cancer research.
Cardiogreen (Indocyanine Green): Reliable Assays & Protocol
2026-05-14
This article explores practical laboratory scenarios where Cardiogreen (Indocyanine Green, SKU B8315) delivers reproducible solutions for cell viability, proliferation, and cytotoxicity assays. Through literature-backed analysis and real-world troubleshooting, it highlights how high-purity Cardiogreen streamlines workflows and data interpretation, ensuring confidence for biomedical researchers and lab technicians.
MTT in Functional Genomics: Precision Cell Viability for Gen
2026-05-13
Discover how MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) enables robust, quantitative cell viability assessment in CRISPR-based genome editing. This article uniquely connects MTT's metabolic readout to state-of-the-art functional genomics, offering new guidance for researchers.
8658 records 18/578 page Previous Next First page 上5页 1617181920 下5页 Last page